Alle afleveringen
494 afleveringen, van nieuw naar oud
-
Oxford based Alethio Therapeutics unveiled a $90M Series A today to advance its therapies for myeloproliferative neoplasms, and also announced for the first time that ATX-011's target will be G6B
5 november 2026 · 15 min
CEO Rohit Batta describes the unmet need in myeloproliferative neoplasms and the rational for targeting G6B, a protein expressed on platelets and megakaryocytes. Their pre-clinical work just earned Alethio an oral presentation at the upcoming ASH Annual Meeting. Lees meer
-
From Montreal: A panel of top venture investors who are based in Montreal discuss the state of biotech in the area and across Canada
4 november 2026 · 20 min
Sofinnova Investments' Maha Katabi, Finchley Healthcare Ventures' Pierre Beauparlant, and Amplitude Ventures' Jean-Francois Pariseau describe the biotech scene here, what Montreal and other Canadian biotech hubs do well, what could be improved, and the environment for entrepreneurs to turn ideas into companies. Lees meer
-
Abingdon, UK based T-Cypher Bio believes that the future of T-cell engagers will focus on intracellular targets - preclinical data on two novel targets, TC25 & TC11, will be at SITC
3 november 2026 · 11 min
CEO Sarah Leonard describes the company's focus and process. The lead program, TC25, is scheduled to be in the clinic in 2028, and the company also has plans to go after auto-immune conditions in addition to oncology.
-
After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)
29 oktober 2026 · 21 min
President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM. Lees meer
-
At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2
27 oktober 2026 · 23 min
CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.
-
London based IMU Biosciences announced today that it will use its immune system profiling platform with 80,000 blood samples from UK Biobank to create a large-scale picture of the human immune system
19 oktober 2026 · 14 min
CEO John Baker describes how the project, done in collaboration with Ultima Genomics and Waters Corporation, will give researcher a tool to better understand the immune system. He also describes how IMU's blood sample based system works, and how it has been used for things such as to better understand which patients will respond to cancer immunotherapies. Lees meer
-
Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1
15 oktober 2026 · 12 min
CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company's pipeline progress.
-
At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research
14 oktober 2026 · 20 min
They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research.
-
Eli Lilly Chairman & CEO David Ricks discusses GLP-1's, Alzheimer's, business development and more
7 oktober 2026 · 24 min
From the company's headquarters in Indianapolis, he describes where he thinks the obesity field could be headed in the next few years, what might be next after beta-amyloid in Alzheimer's, and how he plans to invest for the future.
-
After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress
6 oktober 2026 · 27 min
He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out. Lees meer
-
Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
2 oktober 2026 · 21 min
CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.
-
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
29 september 2026 · 8 min
CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.
-
From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage
28 september 2026 · 9 min
Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.
-
From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections
28 september 2026 · 14 min
CEO David Veitch discusses Cresemba and Zevtera, both of which have momentum in what used to be market with structural barriers to commercial success, but no longer are in most geographies. Plus, a key phase 3 that will read out for Basilea's next mold infection program, fosmanogepix, in 2028. Lees meer
-
Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study
21 september 2026 · 10 min
Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.
-
HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs
16 september 2026 · 15 min
She highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's Pan-KRAS inhibitor, which is still preclinical.
-
HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA
16 september 2026 · 11 min
CEO Paul Peter Tak walks us through how the data has settled, and the steps the company needs to take before officially filing the BLA in Q4. Plus, an update on lung cancer.
-
HCW 2026: H.C. Wainwright & Co. Senior Biotech Analyst Andres Maldonado shares his take on the latest in oncology
16 september 2026 · 9 min
He discusses the big year oncology has had, including in the RAS space, and highlights key catalysts he will be watching throughout the remainder of 2026.
-
HCW 2026: InflaRx designed izicopan from the start with the goal of having a differentiated, best in class profile vs the first marketed C5aR inhibitor. Now more than ever this could be opportune
16 september 2026 · 9 min
Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been pulled from the market in many geographies and is currently in contention at FDA, and how izicopan was built to be different. Now InflaRx needs to prove this to investors and regulators of this. Lees meer
-
HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."
15 september 2026 · 9 min
Pascal Prigent describes the test, which can be used both do diagnose patients and to monitor them. On the therapeutics side, he also discusses IQIRVO, which is marketed by Ipsen, and GENFIT's R&D work in oncology and liver failure.
-
HCW 2026: Scribe Therapeutics, which represents the next generation of CRISPR, had its IPO in July - the first clinical program targets PCSK9
15 september 2026 · 8 min
Co-Founder and CEO Ben Oakes describes the difference between Scribe's approach and the first generation of CRISPR technologies. He then discusses the PCSK9 program, which harnesses epigenetic silencing, and preclinical work on Lp(a) and APOC3.
-
HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader
15 september 2026 · 10 min
CEO Chris Peetz describes the vision for the company, and its acquisition of Bluejay, which will have phase three readouts both this quarter and next. Plus, his explanation of discussions with FDA on volixibat, and more phase 3 data that is scheduled this year on LIVMARLI. Lees meer
-
HCW 2026: With an in-human proof of concept in hand from a rare condition, Prime Medicine is ready to go broader in new indications
15 september 2026 · 9 min
CEO Allan Rein describes the proof of concept Prime has achieved with two patients in Chronic Granulomatous Disease, and discusses the companies plans in Wilson's Disease, Alpha-1 Antitrypsin Deficiency, and Cystic Fibrosis.
-
HCW 2026: H.C. Wainwright & Co.'s Managing Director of Healthcare Investment Banking James Cappuccio says that smaller biotech companies are now able to do large raises for the first time in a while
15 september 2026 · 6 min
He discusses the financing dynamics of the biotech market currently, and comments on whether generalist investors are starting to participate in the sector again.
-
HCW 26: H.C. Wainwright Senior Biotechnology Analyst Mitchell Kapoor touches on current biotech sentiment, the cardiovascular space, in vivo CAR-T, and a pancreatic study to watch
15 september 2026 · 10 min
Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year. Lees meer
-
HCW 26: Ovid Therapeutics CEO Meg Alexander highlights big progress the company has been making in neuroscience on its next-generation GABA-aminotransferase inhibitor and oral KCC2 direct activator
15 september 2026 · 8 min
OV329, the GABA-AT inhibitor, will have photosensitivity data over the coming months while OV4071, the KCC2, will start a ketamine challenge study by the end of the year that should give visibility to a host of important biomarkers to better understand its profile. Lees meer
-
HCW 2026: H.C. Wainwright & Co.'s Vice Chair and President of Capital Markets Richard Gormley believes the elements (M&A, IPOs opening up, other financing opportunities) are still ripe for biotech
14 september 2026 · 7 min
He discusses M&A, which he believes can continue, and the IPO market that finally opened up in 2026. Plus, how positive headlines like Moderna & Merck's cancer vaccine have been causing investors to look at the sector.
-
HCW 2026: Innate Pharma announced a deal with Sobi last month that will move lacutamab towards a registration filing - their partner Astra also has a huge readout coming soon for monalizumab
14 september 2026 · 8 min
CEO Jonathan Dickinson explains the rationale for the Sobi deal and what it means for the development of lacutamab. Plus, preparing for the monalizumab readout and why Innate believes its Nectin 4 is well differentiated and compelling.
-
HCW 2026: Trevi Therapeutics was founded under the premise that cough is a brain problem, not a lung problem - it seems to be playing out in the clinic
14 september 2026 · 6 min
Co-Founder & CEO Jennifer Good shares her take on recent clinical disappointments in the chronic cough space and describes how Trevi's therapy, Haduvio, is different. Plus, an overview of the clinical timelines.
-
HCW 2026: Two key recent papers have validated the use of pramipexole in depression - Alto Neuro believes it has a combination therapy that can make it more tolerable and therefore even better
14 september 2026 · 11 min
Founder and CEO Amit Etkin describes the independent academic work that has been published on this and explains how ALTO-207, which is a combination of pramipexole and ondansetron, appears to have a more tolerable profile. Plus, an update on two other key programs Lees meer
-
HCW 2026: Switzerland based Oculis focuses today on neuro-ophthalmology, which has led them to a pivotal trial in optic neuritis and key mid-stage data coming this year in dry eye disease
14 september 2026 · 9 min
CEO Riad Sherif describes the phase 2 data Oculis delivered in optic neuritis with privosegtor last year and he previews data the company will have soon for licaminlamab in dry eye.
-
Bay Area based Shennon Biotechnologies announced a new CEO today, Cyril Konto, and a $12M raise to advance its T-cell engager programs
14 september 2026 · 11 min
It also announced that the three lead programs will go after small cell lung cancer, ovarian, and hepatocellular carcinoma, though it did not disclose specific targets.
-
UC Berkeley's Gokul Upadhyayula and Eric Betzig are building AI to interpret detailed movies of living cells captured by their MOSAIC microscope
9 september 2026 · 21 min
The work could help guide drug discovery and development by revealing how disease disrupts cells.
-
Bay Area based Moonwalk Biosciences announced a $70M series B today to advance its adipose-targeted RNAi therapies for obesity and cardiometabolic diseases
8 september 2026 · 11 min
Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.
-
Cloverleaf Bio, a spinout out of Yale, announced $33M in seed financing today that will help it advance its work on a tRNA platform in oncology
8 september 2026 · 4 min
Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the lead program targets hepatocellular carcinoma) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund. Lees meer
-
Pareto Securities Healthcare Conference: Sedana Medical's inhaled sedative drug/device combo is currently in front of FDA - they hope to change the ICU with it
2 september 2026 · 8 min
CEO Johannes Doll describes what he believes are the advantages of an inhaled sedative vs the traditional IV. The company already has experience commercializing this in Europe, with 1 out of 7 ICU patients in Germany currently using it. The U.S. PDUFA date is April 16. Lees meer
-
Pareto Securities Healthcare Conference: Pareto's Dan Akschuti highlights the innovation coming out of the Nordics region and companies that have filings in front of FDA
2 september 2026 · 5 min
He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech.
-
Congressman Jake Auchincloss discusses the economic impact of biotech, global competition, and efforts he is taking to solidify funding, modernize regulation, and keep the United States on top
2 september 2026 · 34 min
Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run early stage clinical trials in the U.S. and for it to be less costly for small biotech companies to engage with FDA. Lees meer
-
Pareto Securities Healthcare Conference: BioInvent believes that it has found the next big checkpoint in TNFR2 - this summer they had data both in solid and liquid tumors
2 september 2026 · 8 min
CEO Martin Welschof walks us through recent ASCO (ovarian in combo with Keytruda) and EHA (CTLC) data for BI-1808, and describes why the company believes TNFR2 is a compelling checkpoint with wide applicability. Plus, BI-1206 (FcyRIIB), which will have NCSLC data later this year and BioInvent ultimately hopes to partner. Lees meer
-
Pareto Securities Healthcare Conference: Orexo believes that nasal delivery is superior to other modalities for most uses - they plan to file their naloxone program with FDA immanently
2 september 2026 · 12 min
CEO Nikolaj Sørensen walks us through all the potential benefits of delivering medicines via a nasal spray, would theoretically could even include the ability to cross the BBB for CNS conditions. Naloxone and epinephrine are the most advance, and Orexo also has plans for a nasal spray GLP and vaccines. Lees meer
-
Pareto Securities Healthcare Conference: Hansa Biopharma has a December 19 PDUFA date with FDA for its IgG depleting therapy that hopes to make more patients eligible for kidney transplant
2 september 2026 · 11 min
CEO Renée Aguiar-Lucander describes the idea behind imlifidase and discusses the trial that led to the U.S. filing. Hansa has also recently confidentially filed for an IPO in the United States as well.
-
Pareto Securities Healthcare Conference: Mendus' cellular immunotherapy has been making progress in numerous cancers - being thoughtful about the setting and goal of treatment have been keys
2 september 2026 · 8 min
CEO Erik Manting describes vididencel and the progress the company has been making in AML, CML, and ovarian cancer. Additional CML data is expected in this second half of the year.
-
A focus on cutting edge science and a busy year of presentations and partnerships has made Circio not just one of the fastest growing biotech companies in the Nordic region, but in all of Europe
1 september 2026 · 13 min
Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises. Lees meer
-
Sweden's BioArtic founded the science behind the Alzheimer's medicine Leqembi - 2026 has been busy with a Parkinson's program and a host of partnerships for it brain transporter technology advancing
1 september 2026 · 13 min
CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships. Lees meer
-
Remix Therapeutics announced earlier this summer plans to go public via a reverse merger - it's on the back of clinical data that was presented for its RNA modulator at ASCO
26 augustus 2026 · 9 min
Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year. Lees meer
-
Two fathers of children with rare diseases talk about starting biotech companies to try to create new therapies for their family members and others
26 augustus 2026 · 40 min
Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome. Lees meer
-
LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants
6 augustus 2026 · 17 min
Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well. Lees meer
-
U.S. Science Summit: Biotech veteran Harvey Berger presents an overview of the history of Kendall Square and what is at stake to keep it a leader in life sciences
27 juli 2026 · 15 min
Dr. Berger, who founded Ariad Pharmaceuticals here in 1991, describes Kendall's transition from candy factories, to Polaroid, to what it is today.
-
U.S. Science Summit: Patient perspectives with sickle cell patient advocate Jimi Olaghere and cystic fibrosis advocate Bob Coughlin
27 juli 2026 · 24 min
Jim Olaghere describes signing up for a gene editing treatment clinical trial for sickle cell disease and how it has enabled him to climb mountains and Bob Coughlin recounts the moment when a therapy became available for his son's cystic fibrosis.
-
U.S. Science Summit: Curie.Bio Chairman Alexis Borisy and Parabilis Medicines CEO Mathai Mammen discusses the funding environment for biotech and communicating their work to the public
27 juli 2026 · 24 min
Alexis Borisy recounts the story of Revolution Medicines, which delivered the pancreatic cancer breakthrough this year, and talks about the health of the founder led side of the biotech sector. Mathai Mammen recently took Parabilis public in the largest IPO in biotech history, and describes the science that made it possible. Lees meer